BIO-B - Bio-Rad Laboratories, Inc.
NYSE
->
Healthcare
->
Medical Devices
Hercules,
United States
Type: Equity
BIO-B price evolution
BIO-B
| (in millions $) | 29 Sep 2022 | 29 Jun 2022 | 30 Mar 2022 | 30 Dec 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $517.94 | $596.58 | $802.32 | $470.78 |
| Short term investments | $1332.18 | $1371.08 | $1271.16 | $399.13 |
| Net receivables | $440.8 | $456.62 | $470.71 | $425.74 |
| Inventory | $685.85 | $657.13 | $605.49 | $572.24 |
| Total current assets | $3140.16 | $3249.7 | $3303.42 | $1989.09 |
| Long term investments | $7457.97 | $8086.7 | $9687.98 | $14385.71 |
| Property, plant & equipment | $632.7 | $656.47 | $684.2 | $695.75 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $12058.46 | $12682.13 | $14373.7 | $17775.79 |
| Current liabilities | ||||
| Accounts payable | $142.75 | $158.26 | $160.65 | $141.94 |
| Deferred revenue | ||||
| Short long term debt | $0.45 | -$0.03 | ||
| Total current liabilities | $570.68 | $613.71 | $648.33 | $680.94 |
| Long term debt | $1187.07 | $1186.74 | $1186.34 | $0.01 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $3604.86 | $3759.53 | $4190.78 | $4108.66 |
| Shareholders' equity | ||||
| Retained earnings | $9046.53 | $9210.46 | $10137.63 | $13507.24 |
| Other shareholder equity | -$845.21 | -$533.39 | -$307.86 | -$175.55 |
| Total shareholder equity | $8453.6 | $8922.6 | $10182.92 | $13667.13 |
| (in millions $) | 30 Dec 2021 | 30 Dec 2020 | 30 Dec 2019 | 30 Dec 2018 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $470.78 | $662.21 | $660.67 | $431.53 |
| Short term investments | $399.13 | $328.91 | $453.97 | $413.27 |
| Net receivables | $425.74 | $420.82 | $394.67 | $392.44 |
| Inventory | $572.24 | $622.25 | $554.01 | $583.82 |
| Total current assets | $1989.09 | $2139.84 | $2180.16 | $2023.48 |
| Long term investments | $14385.71 | $9561.14 | $4638.2 | $2655.71 |
| Property, plant & equipment | $695.75 | $693.51 | $701.21 | $508.69 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $17775.79 | $12972.62 | $8008.86 | $5611.07 |
| Current liabilities | ||||
| Accounts payable | $141.94 | $139.45 | $107.01 | $122.45 |
| Deferred revenue | ||||
| Short long term debt | $1.3 | $425.67 | ||
| Total current liabilities | $680.94 | $631.54 | $905.5 | $450.8 |
| Long term debt | $0.01 | $1.26 | $2.38 | $423.7 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $4108.66 | $3092.68 | $2253.8 | $1590.74 |
| Shareholders' equity | ||||
| Retained earnings | $13507.24 | $9268.01 | $5470.78 | $3722.07 |
| Other shareholder equity | -$175.55 | $282.46 | -$87.35 | -$46.96 |
| Total shareholder equity | $13667.13 | $9879.94 | $5755.06 | $4020.33 |
| (in millions $) | 29 Sep 2022 | 29 Jun 2022 | 30 Mar 2022 | 30 Dec 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $680.8 | $691.1 | $700.06 | $732.77 |
| Cost of revenue | $305.71 | $295.12 | $296.5 | $331.87 |
| Gross Profit | $375.09 | $395.98 | $403.56 | $400.9 |
| Operating activities | ||||
| Research & development | $69.45 | $67.03 | $62.64 | $71.87 |
| Selling, general & administrative | $208.35 | $208.83 | $197.39 | $222.65 |
| Total operating expenses | $583.5 | $570.98 | $556.54 | $626.39 |
| Operating income | $97.3 | $120.12 | $143.52 | $106.38 |
| Income from continuing operations | ||||
| EBIT | $97.3 | $120.12 | $143.52 | $106.38 |
| Income tax expense | -$44.94 | -$295.7 | -$1001.4 | -$464.4 |
| Interest expense | -$11.66 | -$10.72 | -$4.05 | -$0.36 |
| Net income | ||||
| Net income | -$164.23 | -$927.18 | -$3369.61 | -$1573.66 |
| Income (for common shares) | -$164.23 | -$927.18 | -$3369.61 | -$1573.66 |
| (in millions $) | 30 Dec 2021 | 30 Dec 2020 | 30 Dec 2019 | 30 Dec 2018 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2922.55 | $2545.63 | $2311.66 | $2289.41 |
| Cost of revenue | $1256.88 | $1109.7 | $1049.96 | $1062.16 |
| Gross Profit | $1665.66 | $1435.92 | $1261.7 | $1227.25 |
| Operating activities | ||||
| Research & development | $258.36 | $227.8 | $196.61 | $199.2 |
| Selling, general & administrative | $853.17 | $799.37 | $811.73 | $834.78 |
| Total operating expenses | $2368.41 | $2136.87 | $2058.3 | $2096.14 |
| Operating income | $554.13 | $408.76 | $253.36 | $193.27 |
| Income from continuing operations | ||||
| EBIT | $554.13 | $408.76 | $253.36 | $193.27 |
| Income tax expense | $1192.25 | $1101.37 | $502.41 | $147.04 |
| Interest expense | -$1.55 | -$21.86 | -$23.42 | -$23.96 |
| Net income | ||||
| Net income | $4245.9 | $3806.27 | $1758.67 | $365.61 |
| Income (for common shares) | $4245.9 | $3806.27 | $1758.67 | $365.61 |
| (in millions $) | 29 Sep 2022 | 29 Jun 2022 | 30 Mar 2022 | 30 Dec 2021 |
|---|---|---|---|---|
| Net income | -$164.23 | -$927.18 | -$3369.61 | -$1573.66 |
| Operating activities | ||||
| Depreciation | $42.5 | $42.6 | $42 | $43.7 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $7.51 | $50.2 | $46.31 | $157.92 |
| Investing activities | ||||
| Capital expenditures | -$24.06 | -$14.26 | -$28.9 | -$43.24 |
| Investments | $39.9 | -$128.62 | -$883.06 | $67.71 |
| Total cash flows from investing | -$84.91 | -$141.41 | -$911.96 | -$554.48 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | -$0.11 | -$0.15 | $1186.12 | -$1.38 |
| Total cash flows from financing | -$8.77 | -$121.33 | $1190.29 | $4.63 |
| Effect of exchange rate | $7.5 | $6.79 | $6.88 | -$1.46 |
| Change in cash and equivalents | -$78.66 | -$205.75 | $331.52 | -$393.39 |
| (in millions $) | 30 Dec 2021 | 30 Dec 2020 | 30 Dec 2019 | 30 Dec 2018 |
|---|---|---|---|---|
| Net income | $4245.9 | $3806.27 | $1758.67 | $365.61 |
| Operating activities | ||||
| Depreciation | $173.1 | $175.2 | $174.5 | $138.1 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $656.52 | $575.33 | $457.9 | $285.49 |
| Investing activities | ||||
| Capital expenditures | -$120.8 | -$98.92 | -$98.53 | -$129.82 |
| Investments | -$84.73 | $119.6 | -$39.92 | -$68.69 |
| Total cash flows from investing | -$784.44 | -$60.25 | -$208.89 | -$186.98 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | -$3.02 | -$426.94 | -$0.64 | -$2.96 |
| Total cash flows from financing | -$55.43 | -$523.04 | -$22.76 | -$48.68 |
| Effect of exchange rate | -$12.64 | $12.43 | $2.24 | -$0.66 |
| Change in cash and equivalents | -$195.98 | $4.46 | $228.49 | $49.18 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $2.80B |
|---|---|
| EBITDA | $638.12M |
| EBIT | $467.32M |
| Net Income | -$6.03B |
| Revenue Q/Q | -8.87% |
| Revenue Y/Y | -5.87% |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | -42.43% |
| ROE | -58.55% |
| Debt/Equity | 0.30 |
|---|---|
| Net debt/EBITDA | 4.84 |
| Current ratio | 5.50 |
| Quick ratio | 4.30 |